Document is current
Any future updates will be listed below
-
Authors
Konig, Manige http://orcid.org/0000-0002-1584-8309
Riddle, Matthew C.
Colhoun, Helen M.
Branch, Kelley R.
Atisso, Charles M.
Lakshmanan, Mark C.
Mody, Reema
Raha, Sohini
Gerstein, Hertzel C.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01394952 at ClinicalTrials.govDocuments that mention this clinical trial
New drugs in preclinical and early stage clinical development in the treatment of heart failure
https://doi.org/10.1080/13543784.2019.1551357
Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
https://doi.org/10.1186/s12933-021-01386-4
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
https://doi.org/10.2337/ds16-0026
Nonglycemic Outcomes of Antidiabetic Medications
https://doi.org/10.2337/cd18-0015
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
https://doi.org/10.1016/j.ahj.2015.02.002
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
https://doi.org/10.2337/dc15-2237
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
https://doi.org/10.1016/j.clinthera.2015.08.001
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
https://doi.org/10.1186/s12933-020-01179-1
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
https://doi.org/10.1016/j.ahj.2015.12.009
A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes
https://doi.org/10.1186/s12933-022-01594-6
-
Funding
Funding for this research was provided by:
eli lilly and company
- License Information
-
More Information
Article History
Received: 12 July 2021
Accepted: 21 September 2021
First Online: 25 September 2021
Declarations
:
: The REWIND protocol was approved by research ethics boards for all sites. All participants provided written informed consent. The trial was carefully monitored by members of an independent data monitoring committee who reviewed accruing and unblinded data every 6 months.
: All authors have reviewed and approved the content of this manuscript for publication.
: MK and RM are employees and shareholders of Eli Lilly and Company. CMA and MCL are former employees and shareholders of Eli Lilly and Company. MCR reports grants to his institution from Eli Lilly and Company, AstraZeneca, and Novo Nordisk; honoraria for consulting from Adocia, DalCor, GlaxoSmithKline, and Theracos; and honoraria for speaking from Sanofi. HMC reports research grants from Eli Lilly and Company, AstraZeneca, Regeneron, Pfizer, Roche, Sanofi, and Novo Nordisk; honoraria for speaking from Eli Lilly and Company and Regeneron; consulting fees from Eli Lilly and Company, Novartis, Regeneron, Sanofi, and Novo Nordisk; and shares in Bayer and Roche. KRB reports research grants to his institution from Bayer, Eli Lilly and Company, and Sanofi; and consulting fees from Bayer, Janssen, and Sana. SR is an employee of Eli Lilly and Company. HCG holds the McMaster-Sanofi Population Health Institute Chair in Diabetes Research and Care. He reports research grants from Eli Lilly and Company, AstraZeneca, Merck, Novo Nordisk, and Sanofi; honoraria for speaking from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, and Sanofi; and consulting fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Merck, Novo Nordisk, Janssen, Sanofi, Kowa, and Cirius.
